149 related articles for article (PubMed ID: 26520723)
1. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
2. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
3. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma.
Zwahlen DR; Martin JM; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):853-8. PubMed ID: 18164856
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy for stage IIA and IIB testicular seminoma: peripheral dose calculations and risk assessments.
Mazonakis M; Berris T; Lyraraki E; Damilakis J
Phys Med Biol; 2015 Mar; 60(6):2375-89. PubMed ID: 25716274
[TBL] [Abstract][Full Text] [Related]
6. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.
Simone CB; Kramer K; O'Meara WP; Bekelman JE; Belard A; McDonough J; O'Connell J
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):242-9. PubMed ID: 21236595
[TBL] [Abstract][Full Text] [Related]
7. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.
Efstathiou JA; Paly JJ; Lu HM; Athar BS; Moteabbed M; Niemierko A; Adams JA; Bekelman JE; Shipley WU; Zietman AL; Paganetti H
Radiother Oncol; 2012 Apr; 103(1):12-7. PubMed ID: 22391053
[TBL] [Abstract][Full Text] [Related]
9. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy treatment planning for testicular seminoma.
Wilder RB; Buyyounouski MK; Efstathiou JA; Beard CJ
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e445-52. PubMed ID: 22436787
[TBL] [Abstract][Full Text] [Related]
11. Second primary cancer in irradiated stage I testicular seminoma.
Stein ME; Steiner M; Lachter J; Kessel I; Moskovitz B; Kuten A
Strahlenther Onkol; 1993 Nov; 169(11):672-7. PubMed ID: 8248844
[TBL] [Abstract][Full Text] [Related]
12. External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis.
Jacobsen KD; Olsen DR; Fosså K; Fosså SD
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):95-102. PubMed ID: 9212009
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience.
Hallemeier CL; Pisansky TM; Davis BJ; Choo R
Urol Oncol; 2013 Nov; 31(8):1832-8. PubMed ID: 22537538
[TBL] [Abstract][Full Text] [Related]
14. Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy.
Hallemeier CL; Davis BJ; Pisansky TM; Choo R
Urol Oncol; 2014 May; 32(4):496-500. PubMed ID: 24332645
[TBL] [Abstract][Full Text] [Related]
15. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
Kourinou KM; Mazonakis M; Lyraraki E; Papadaki HΑ; Damilakis J
Phys Med; 2019 Jan; 57():100-106. PubMed ID: 30738513
[TBL] [Abstract][Full Text] [Related]
16. Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma.
Hoppe BS; Mamalui-Hunter M; Mendenhall NP; Li Z; Indelicato DJ
Am J Clin Oncol; 2013 Feb; 36(1):31-7. PubMed ID: 22134517
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic follow-up in testicular seminoma patients exposed to adjuvant radiotherapy.
Gamulin M; Kopjar N; Grgić M; Ramić S; Viculin T; Petković M; Garaj-Vrhovac V
Coll Antropol; 2010 Jun; 34(2):455-65. PubMed ID: 20698117
[TBL] [Abstract][Full Text] [Related]
18. Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma.
Mazonakis M; Kachris S; Damilakis J
Med Phys; 2020 Jul; 47(7):2805-2813. PubMed ID: 32266979
[TBL] [Abstract][Full Text] [Related]
19. Management of clinical stage I testicular pure seminoma. Report on 42 patients and review of the literature.
Porcaro AB; Antoniolli SZ; Schiavone D; Maffei N; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):77-80. PubMed ID: 12161941
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).
Chan R
J Clin Oncol; 2005 Sep; 23(27):6806; author reply 6806-7. PubMed ID: 16170196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
